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The severity of complications of allogeneic hematopoietic stem cell transplantation (HSCT) is governed
mainly by the status of immune reconstitution. In this study, we investigated differences in immune
reconstitution with different cell sources and the association between the kinetics of immune reconstitution
and mortality. Immunophenotyping was performed every 2 weeks in children who had undergone
HSCT between 2004 and 2008 at University Medical Center Utrecht. Lymphocyte reconstitution in the ﬁrst
90 days after HSCT was studied in relation to mortality in 3 HSCT groups: matched sibling bone marrow (BM)
recipients (35 patients), unrelated BM recipients (32 patients), and unrelated cord blood recipients
(36 patients). The median age of recipients was 5.9 years (range, 0.1-21 years). The nature and speed of T cell,
B cell, and natural killer (NK) cell reconstitution were highly dependent on the cell source. In the ﬁrst 90 days
after HSCT, faster B cell and NK cell reconstitution and delayed T cell reconstitution were shown in unrelated
cord blood recipients compared with matched sibling BM and unrelated BM recipients. Of the lymphocyte
subsets investigated, a large number of NK cells and a more rapid CD4þ immune reconstitution over time,
resulting in sustained higher CD4þ counts, were the only predictors of a lower mortality risk in all cell
sources. The ﬁnal model showed that during the ﬁrst 90 days, patients with an area under the CD4þ cell
receiver- operating curve of >4,300 cells/day and no peak in CD4þ cell counts had the highest likelihood of
survival (hazard ratio for mortality, 0.2; 95% conﬁdence interval, 0.06-0.5). Our data indicate that CD4þ
kinetics may be used to identify patients at greatest risk for mortality early after HSCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) using bone marrow (BM), peripheral blood, or cord
blood (CB) from either matched related donors or unrelated
donors is an established therapy for a variety of malignant
diseases (eg, acute and chronic leukemias, lymphoma, mye-
lodysplastic syndrome) and nonmalignant diseases (eg, bone
marrow failure syndromes, inborn errors of metabolism such
as Hurler syndrome, immune deﬁciencies, and hemoglo-
binopathies) [1,2]. Since the ﬁrst report of related CB trans-
plantation in a child with Fanconi anemia in 1989 [3], the use
of related and unrelated CB as a stem cell source has
increased rapidly, especially in children [4,5], because of its
availability and less-stringent HLA-matching criteria. Unfor-
tunately, the success of HSCT remains restricted by
transplantation-associated complications, including graft-
versus-host disease (GVHD) and infections and by relapse
of the underlying disease. Immune reconstitution has
a pivotal role in these complications.dgments on page 311.
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12.10.010Several studies have shown that the quantity and quality
of immune reconstitution is correlated with long-term clin-
ical outcomes, including survival, presence of GVHD, viral
disease, and relapse rate, in both children and adults [6-14].
Both nonspeciﬁc cell populations (eg, total lymphocyte
count) and more speciﬁc subpopulations (in which most
studies identiﬁed CD4þ helper T cells as the most important
cell type [11,14]), as well as changes in plasma markers (eg,
IL-10, IFN-a, Toll-like receptors [15-17]) have been associated
with clinical outcomes. Various other factors, including
source, minor and major histo(in)compatibilities, occurrence
of chronic GVHD, and age, have been shown to inﬂuence
immune reconstitution [18-24]. Whereas previous studies
have characterized differences in the long-term composition
of the Tcell and B cell compartments after CB and BMHSCTat
several years after HSCT [25], there have been no detailed
studies of early immune reconstitutiondthe phase most
critical for outcomedin recipients of unrelated CB (u-CB),
matched sibling BM (id-Sib), or unrelated BM (u-BM).
Previous studies evaluating the relationship between
immune reconstitution and clinical outcomes have involved
mainly adult patients [8,11-14,26]. These data for adults
cannot be readily extrapolated to children because of
differences in the 2 populations; for example, adults
have higher rates of opportunistic infection and GVHD
[23,27] and experience more prolonged thymus-dependentTransplantation.
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evidence that speciﬁc lymphocyte subsets can predict long-
term outcomes in pediatric patients. The association
between immune reconstitution and clinical outcomes in
children has been investigated mainly 200 days or longer
after HSCT [29-31], which means that early predictors have
not yet been studied. Two previous studies of early immune
reconstitution in pediatric populations used diverse
endpoints. Szabolcs and Niedzwiecki [24] studied immune
reconstitution at day þ50 post-HSCT in u-CB recipients in
relation to opportunistic infections and found that patients
with opportunistic infections had higher levels of CD8þ T
cells expressing/secreting HLA-DR, IFN-g, granzyme A and B,
and perforin [24]. Kalwak et al. [20], in a study of 27 children
who received a BM or peripheral blood progenitor cell
transplantation, found that the presence of cytomegalovirus
reactivation and/or GVHDwas associated with a signiﬁcantly
lower ratio of CD4þCD45RAþ to CD4þCD45ROþ cells on
day þ30 post-HSCT.
The identiﬁcation of HSCT recipients at increased risk for
mortality would facilitate the development of novel treat-
ment strategies. Consequently, in the present study, we
investigated the variability in immune reconstitution among
various cell sources and examined the association between
the kinetics of immune reconstitution and mortality after
HSCT with id-Sib, u-BM, and u-CB.
METHODS
Setting and Patients
The study was performed in the University Medical Center Utrecht
(UMC Utrecht), 1 of the 2 pediatric bone marrow transplantation centers in
The Netherlands. All childrenwho underwent allogeneic HSCT, regardless of
indication, between May 2004 and July 2008 at UMC Utrecht were
prospectively included in this study. Patients were enrolled in the researchTable 1
Patient Characteristics and Outcomes
Stem Cell Source
Id-Sib* U-BM
Patient characteristics
Number 35 32
Age, y, median (range) 8.7 (0.4-16.8) 7.5 (1.3-
Male sex, % 54 66
Donor age, y, median (range) 10 (3-28) 34 (19-4
Total body irradiationebased conditioning, % 28 23
Underlying disease, %y 50 77
ATG, %z 0 68 Genz
GVHD prophylaxis CsA CsA þ m
Granulocyte colony-stimulating factor, % 0 0
HLA matching, % matchedx 100 65
Number of HSCTs: 1, 2, 3 32, 3, 0 28, 4, 0
Follow-up, mo, median (range) 58.3 (1.8-103) 64.8 (3.5
Outcomes
1-y survival, % 89 72
1-y event-free survival, %{ 71 59
Acute GVHD, %k 23 56
Chronic GVHD, %** 20 19
CsA indicates cyclosporine A.
* id-Sib was the preferred cell source, followed by either 10/10-matched u-BM or
patients with an inborn error of metabolism, u-CB was the preferred cell source.
y Nonmalignant (eg, inborn errors of metabolism, immunodeﬁciencies, autoimm
lymphoblastic leukemia, acute myelogenous leukemia, myelodysplastic syndrome
z u-BM and u-CB recipients received serotherapy with 10 mg/kg ATG rabbit (Th
Homburg, Germany) in patients with acute lymphoblastic leukemia.
x HLA matching was based on high-resolution typing for class I and class II (10 an
resolution criteria were used (loci A and B by low-resolution typing and DRB1 by
account.
{ Event-free survival was deﬁned as “alive with engraftment” (>95% chimerism
k Acute GVHD was diagnosed and graded according to the Glucksberg criteria [1
** Severity of chronic GVHD was graded according to Shulman et al. [2].protocol after the patient or a parent provided written informed consent.
The study was approved by theMedical Ethics Committee of UMC Utrecht in
accordance with the Helsinki Declaration of 1975, revised in 2008. Proce-
dures, conditioning regimens, and supportive care depended on the cell
source, as shown in Table 1.
Immunophenotyping
Immunophenotyping was performed on whole-blood samples every
other week once a leukocyte count >0.4  109/L was detected. Absolute
numbers of T cells (CD3þ), helper T cells (CD3þCD4þ), cytotoxic T cells
(CD3þCD8þ), B cells (CD19þ), and natural killer (NK) cells
(CD3-CD16þCD56þ) were determined using TruCOUNT technology (BD
Biosciences, Erembodegem, Belgium). A volume of 20 mL of CD3-FITC, CD45-
PerCP, CD19-APC or CD3-FITC, CD8-PE, CD45-PerCP, CD4-APC reagent
(MultiTEST; BD Biosciences) was added to a TruCOUNT tube containing
a known quantity of beads, followed by 100 mL of EDTA-treated whole blood
and incubated for 15minutes at room temperature. RBCs were subsequently
lysed for 15 minutes with 450 mL of FACS Lysing Solution (BD Biosciences).
Samples were acquired using a FACSCalibur and analyzed with Multiset
software (BD Biosciences).
Qualitative analysis of B cell, T cell, and NK cell compartments
were performed as described previously [29]. For the analysis of T cell
subsets, 50-mL aliquots of heparinized blood were incubated with mono-
clonal antibodies CD45RA-FITC, CD4-PE, CD8-PE, CD3-PerCP-Cy5.5, and
CD27-APC. After erythrocyte lysis, cells were analyzed on a FACSCalibur
using Cellquest software (BD Biosciences), as described previously [29].
Based on the expression of CD27 and CD45RA, the CD4þ and CD8þ T cell
compartments were divided into naïve T cells and effector and memory
T cells, and the naïve/memory ratio was calculated.
Kinetics of Immune Reconstitution
Various lymphocyte subsets were investigated in relation to outcome
during the ﬁrst 3months after HSCT. Patients exhibiting a sustained increase
in lymphocyte count might have a better chance of survival than those
with ﬂuctuating reconstitution in the ﬁrst 90 days after HSCT. Peaks in T cell
counts during this period might reﬂect an underlying event, such as a viral
infection or acute GVHD, which in turn could affect long-term outcome.
Therefore, instead of a cross-sectional approach as used in most previous
studies, markers were measured and analyzed at various time points post-P Value
U-CB Total
36 103
18.9) 2.5 (0.1-21.2) 4.9 (0.1-21) .021
44 54 .215
6) 0 0 (0-46)
21 24 .381
31 51 .14
yme, 3 Fresenius 100 Genzyme 75
ethotrexate CsA þ prednisolone
100 35
18 61
33, 2, 1 93, 9, 1
-99) 60.4 (1.1-97) 24.3 (1.1-67) .83
78 79 .212
72 68 .932
28 35 .142
25 21 .541
6/6-matched u-CB, followed bymismatched u-CB (4-6/6) as a third option. In
une disorders, bone marrow failure syndromes) and malignant (eg, acute
).
ymoglobulin; Genzyme, Cambridge, MA) or 20 mg/kg ATG (Fresenius, Bad
tigens: HLA-A, -B, -C, -DR, and -DQ) for u-BM. For u-CB donors, intermediate
high-resolution typing) [12]. An HLA-DPB1 mismatch was not taken into
) and without evident relapse (in case of malignant indication).
].
Figure 1. Neutrophil engraftment (time to reach at least 500 neutrophils) in
the id-Sib, u-BM, and u-CB groups.
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early after transplantation. The maximum T cell, B cell, NK cell, and subset
cell counts and times to reach these counts during the ﬁrst 90 days post-
HSCT, as well as the ratio of maximum CD4þ/CD8þ cell counts, were
determined. The area under the cell-time curve from 0 to 90 days (AUC0-90)
was calculated for T cells and B cells using the trapezoidal method, as
described in Appendix 1. A peak was deﬁned as a >50% increase in the
number of cells relative to the number in the previous measurement and
after which the number decreased back to baseline (ie, number of cells
within 20% of the original valuewithin the subsequent 20 days). An example
is shown in Appendix 1. All values for lymphocyte subsets were compared
with age-related reference values [32].
Endpoint
The main study endpoint was mortality (either due to relapse or
transplantation-related) with a minimum follow-up time of 35 months.
Data Analysis
For the analyses, patients were divided into 3 groups based on stem cell
source: id-Sib, u-CB, and u-BM. Differences in patient characteristics and
in the kinetics of immune reconstitution among the 3 groups were
assessed using the Kruskal-Wallis test for continuous data and c2 test for
categorical data. Patient age was divided into quartiles, and differences in all
lymphocyte subsets in these age quartiles for each cell source were
determined using the Kruskal-Wallis test. The association between the
kinetics of the lympohocyte subsets and mortality was assessed using
univariate and multivariate analyses with multiplicative intensity models,
a generalization of Cox regression (using R version 2.12.2, "survival" library;
R Foundation for Statistical Computing, Vienna, Austria). Data from patients
who died within 90 days post-HSCT were included by extrapolation and
were excluded from the AUC0-90 analyses, and results were checked for
consistency. The analytical methods are described in further detail in
Appendix 2.
The ability of lymphocyte subsets identiﬁed in the ﬁnal model to
discriminate between patients who did or did not die within 2 years post-
HSCT was assessed using receiver- operating characteristic (ROC) curves
[33] with the "risk- set ROC" library in R version 2.12.2 [34]. The ROC curve
analysis is described in more detail in Appendix 3.
RESULTS
Patients and Characteristics
A total of 109 HSCT recipients underwent transplantation
between May 2004 and July 2008 at UMC Utrecht. No
samples were collected in 6 patients, who were excluded
from the analyses, leaving a total of 103 patients for this
study. The median follow-up was 59 months (range,
1-103 months). Thirty-ﬁve patients (34%) received an id-Sib
graft, 32 (31%) received a u-BM graft, and 36 (35%) received
a u-CB graft. Patient age, donor, use of antithymocyte glob-
ulin (ATG), HLA matching, use of granulocyte colony-
stimulating factor (GCS-F), and GVHD prophylaxis varied
among the groups (Table 1). These differences were related
mainly to differences in protocols used for the various cell
sources (eg, donor age, use of GCS-F in u-CB and ATG in u-BM
recipients). The u-CB recipients were signiﬁcantly younger
than the u-BM recipients, and inborn errors of metabolism
were more common in the u-CB recipients compared with
the other 2 groups.
The probability of 1-year survival was 79%, and that of
1-year event-free survival was 68%. Twenty patients died
from transplantation-related causes (6 from GVHD, 4 from
multiorgan failure, 3 from invasive fungal infection, 3
from noninfectious lung injury, 1 from Epstein-Barr
viruseassociated posttransplantation lymphoproliferative
disorder, 1 from viral infection, and 2 due to cardiac toxicity),
and 10 (of 52 patients with malignant indication) died due to
disease relapse. The median time to death was 176 days
(range, 34-754 days). Five of these 30 patients died within 90
days after HSCT, due to invasive fungal infection (2 patients),
multiorgan failure (2 patients), or lung insufﬁciency
(1 patient). Outcomes are summarized in Table 1. Fivepatients did not engraft (2 id-Sib recipients,1 u-BM recipient,
and 2 u-CB recipients). In these 5 patients, leukocyte counts
exceeded 0.4  109/L, and samples for immunophenotyping
were collected.Immune Reconstitution after HSCT
All patients had leukocyte counts exceeding 0.4  109/L
within 90 days of transplantation. A total of 591 blood
samples (mean, 5.7 samples per patient) were collected
between day 0 and dayþ90 post-HSCT. In 2 id-Sib recipients,
2 u-BM recipients, and 1 u-CB recipient, the ﬁrst blood
samples were collected after 90 days post-HSCT. These 5
patients were excluded from further analyses. A total of 165
measurements were recorded in id-Sib recipients (mean,
4.7 per patient), 167 measurements were recorded in u-BM
recipients (mean, 5.2 per patient), and 259 measurements
were recorded in u-CB recipients (mean, 7.2 per patient). The
ﬁrst measurement of immune reconstitution was performed
at a median of 24 days post-HSCT (22 days for id-Sib recip-
ients, 30 days for u-BM recipients, and 20 days for u-CB
recipients; P ¼ .002). The time to a minimum neutrophil
count of 500 cells/uL by type of graft is shown in Figure 1
(P ¼ .097).
There were signiﬁcant differences in lymphocyte
subtypes among the 3 donor groups (Figure 2). In the ﬁrst
90 days post-HSCT, B cell immune reconstitution was more
rapid in u-CB recipients than in u-BM and id-Sib recipients
(Figure 2A and B). Absolute numbers of CD4þ and CD8þ
T cells were higher in id-Sib and u-BM recipients compared
with u-CB recipients (Figure 2C-H). The differences in
immune reconstitution might be related to the occurrence of
peak CD4þ or CD8þ cell counts during the ﬁrst 90 days post-
HSCT in the different groups (Figure 2F and I). In the ﬁrst 90
days post-HSCT, the majority of T cells were of the effector-
memory phenotype, although id-Sib recipients exhibited
a relatively high proportion of naïve T cells in the CD4þ and
CD8þ T cell populations compared with the other groups
(Figure 2J and K). CD8þ cell immune reconstitution occurred
more rapidly, and the CD4/CD8 ratio was inversed in u-BM
recipients compared with the other groups (Figure 2L).
Absolute numbers of NK cells were higher in u-CB recipients
than in id-Sib and u-BM recipients (Figure 2M). None of the
lymphocyte subsets was associated with the age of the
patient in any of the donor groups (data not shown).
P < .001
P < .001
P = .683 P < .001
P = .026
P = .647
P = .485
P = .561
P = .207
P = .707 P = .445
P = .249
P < .001
P = .084 P = .001
P = .040
P < .001
P = .229
P = .045
P = .304 P = .002
P < .001
P = .283 P < .001 P = .001
P = .003
P = .003
P = .048 P < .001
P = .053
P = .026
P = .659P < .001
P = .014
P = .020
P = .431 P = .203
P < .001
P = .114
Figure 2. Kinetics of the lympohocyte subsets per cell source in the ﬁrst 90 days. (A) Maximum number of CD19þ cells. (B) Area under the CD19þ cell-time curve
(AUC0-90). (C) Maximum number of CD4þ cells. (D) Number of CD4þ cells at day 90 (as a cross-sectional marker). (E) CD4þ AUC0-90. (F) Occurrence of a peak in CD4þ
cell counts within this time period. (G) Maximum cell number of CD8þ cells. (H) CD8þ AUC0-90. (I) Occurrence of a peak in CD8þ cell counts within this time period. (J)
Ratio of CD4þ naïve to memory cells. (K) Ratio of CD8þ naïve to memory cells. (L) Ratio of CD4þ to CD8þ cells. (M) Maximum number of NK cells. The white box
represents the 25th to the 75th percentile of the data. Dots represent extreme values. The triangle represents median value. The gray box approximates the 95% CIs of
the median value.
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Figure 3. Overall survival in the id-Sib, u-BM, and u-CB groups.
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Overall survival did not differ signiﬁcantly among the 3
cell source groups (Figure 3). In addition, neither sex nor age
at HSCT was a predictor of mortality. The hazard function of
the association with mortality of most lymphocyte subsets
differed among the 3 groups, and the group sizes were too
small to allow detection of within-group associations. In
univariate analysis, rapid immune reconstitution of NK cells
showed a trend toward decreased mortality in all 3 cell
source groups (Table 2). The hazard ratio (HR) for mortality-
associated higher maximum of NK cells (NK/100) using
a linear function was 0.79 (95% conﬁdence interval [CI],
0.57-1.11) in the id-Sib group, 0.93 (95% CI, 0.80-1.10) in the
u-CB group, 0.85 (95% CI, 0.63-1.15) in the u-BM group, and
0.88 overall (95% CI, 0.77-1.00; P¼ .058). For CD4þ cell count,
a more rapid and sustained CD4þ immune reconstitution
over time, reﬂected by a higher CD4þ AUC0-90, was associated
with reduced mortality in all 3 groups (Table 2 and Figure 3).
The HR for mortality associated with higher CD4þ AUC0-90
(AUC/1000) was 0.26 (95% CI, 0.06-1.15) in the id-Sib group,
0.09 (95% CI, 0.02-0.51) in the u-CB group, and 0.23 (95% CI,
0.04-1.21) in the u-BM group. The model of CD4þ AUC0-90
using a linear function was superior to that using a loga-
rithmic or parabolar function (based on HR, P values, andTable 2
Results of the Univariate and Multivariate Cox Regression Models
Variable Number HR 95% CI P Value
Univariate model
CD4þ AUC0-90 25 0.18 0.07-0.50 .001
Occurrence of peak day0-90 2.47 0.89-6.85 .083
NK cells 25 0.88 0.77-1.00 .058
Multivariate model
CD4þ AUC0-90 25 0.08 0.02-0.31 <.001
Occurrence of peak day0-90 6.74 2.03-22 .002
Analysis by donor source
id-Sib (CD4þ AUC0-90) 9 0.12 0.02-0.79 .028
Occurrence of peak day0-90 8.66 1.40-53 .020
u-BM (CD4þ AUC0-90) 9 0.05 0.01-0.45 .007
Occurrence of peak day0-90 2.34 0.50-10.9 .279
u-CB (CD4þ AUC0-90) 7 0.04 0.005-0.28 .002
Occurrence of peak day0-90 104 26-418 <.001
Subanalysis
CD4þ AUC0-90 >4,300
without peak day0-90
18 0.18 0.060-0.55 .003
The CD4þ AUC0-90 was divided by 10,000, and NK cells were divided by 100
in these analyses.diagnostic plots). A subset analysis of the ratio of CD4þ naïve
cells to memory cells showed no correlation between this
ratio and survival. A peak in CD4þ cell count within the ﬁrst
90 days post-HSCTwas associated with higher mortality (HR,
2.4; 95% CI, 0.89-6.9).
The ﬁnal multivariate model included the occurrence of
a peak in the ﬁrst 90 days post-HSCT, CD4þ AUC0-90, and
mortality (Table 2). The results of this model were similar for
the 3 groups. The number of CD4þ cells at day 90 (as cross-
sectional marker) did not differ signiﬁcantly among the
groups (Figure 2D) and was not associated with mortality
(HR, 0.75; 95% CI, 0.5-1.2). No association was found within
each group as well (id-Sib: HR, 0.52; 95% CI, 0.2-1.2; u-CB:
HR, 0.59; 95% CI, 0.3-1.3; u-BM: HR, 1.06; 95% CI, 0.7-1.6).
The ﬁnal multivariate model was able to predict mortality
(AUCROC, 0.74) and determined an optimal cutoff value for
the CD4þ AUC0-90 of 4,300 cells/day (AUCROC, 0.69) in all
patients regardless of donor group (Figure 4A-C). Patients
with a CD4þ AUC0-90 > 4,300 cells/day and no peak in CD4þ
cell count had the best survival (HR for mortality, 0.2; 95% CI,
0.06-0.5; P ¼ .002) (Figure 4D and Table 2). No association
between acute GVHD and T cell immune reconstitution was
found. Moreover, there was no difference in the AUC of CD4þ
in patients with acute GVHD and those without acute GVHD
(median, 5,565; range, 123-77,206 and median, 5,233; range,
15-16,876, respectively: P ¼ .825).
DISCUSSION
This study demonstrates that the kinetics of immune
reconstitution early after HSCT differed among id-Sib, u-BM,
and u-CB recipients. In the ﬁrst 90 days after HSCT, B cell and
NK cell reconstitution was faster, and T cell reconstitution
was delayed in u-CB recipients compared with id-SIB and u-
BM recipients. Regardless of cell source, a more rapid CD4þ
immune reconstitution over time, resulting in sustained
higher CD4þ cell counts, is a predictor of a lower probability
of death, whereas patients with an early peak in CD4þ cell
counts are at risk for mortality. The kinetics of CD4þ cells are
easy to measure in daily clinical practice using a speciﬁc
formula (available from http://www.umcutrecht.nl/subsite/
SCT-kinderen/Professionals/PKPD-studies/AUC-CD4-calculation)
and might help identify patients at risk for mortality
(relapse/transplantation-related mortality) early after allo-
geneic HSCT.
The nature and speed of T cell, B cell, and NK cell
immune reconstitution are highly dependent on cell source
[18,23-25,35]. In line with observations in adults, we found
increased numbers of B cells early, but much slower T cell
immune reconstitution in u-CB recipients [23,36,37]. The
relatively rapid CD8þ T cell immune reconstitution in u-BM
recipients is in line with previous reports and led to an
inverse CD4/CD8 ratio [36,37]. This inverted CD4/CD8 ratio
was not seen in the u-CB or id-Sib recipients [38,39]. The
trend toward improved survival after rapid NK cell recon-
stitution is consistent with previous studies [40]. Rapid and
sustained recovery of T helper cells predicted a lower
mortality risk regardless of cell source. A peak of CD4þ cells
in the ﬁrst 90 days post-HSCT was predictive of higher
mortality. Although not completely understood, this peak
may reﬂect the occurrence of acute GVHD or lymphoprolif-
eration owing to known or unknown (viral) infection. These
ﬁndings are consistent with experiencewith HIV infection, in
which a high baseline CD4þ count is positively associated
with long-term survival [41-43]. Several other HSCT studies
have identiﬁed CD4þ cell count as a major determinant of
Figure 4. (A-C) Kaplan-Meier curve of CD4þ AUC0e90 using the cutoff value in
relation to survival in the id-Sib (A), u-BM (B), and u-CB (C) groups. (D) CD4þ
I.H. Bartelink et al. / Biol Blood Marrow Transplant 19 (2013) 305e313310outcome, with a high CD4þ cell count being a predictor of
a lower incidence of cytomegalovirus infection, bacterial
infection, and mortality [7,11,13,14]. However, these studies
involved mainly adult patients, and none included u-CB or
other cell sources.
Consistent with the ﬁndings of Small et al. [22], recipient
age was not a predictor for either immune reconstitution
during the ﬁrst 90 days post-HSCT or of mortality after HSCT.
In contrast, others have reported differences in immune
reconstitution between adults and children and also among
children of different ages, within the ﬁrst 90 days post-HSCT
[20,23,44]. Kalwak et al. [20] did not study cell source as
a covariate, which might explain the differences between
their ﬁndings and ours. Several other studies of immune
reconstitution after pediatric HSCT used cutoff values (5th or
50th percentile of age-related reference values) as a study
endpoint [30,31]. On the basis of the negative associations
among age, immune recovery, and mortality in the ﬁrst
90 days after HSCT, our ﬁndings indicate that a minimum cell
count is essential for effective immune reconstitution, and
that age-related reference values are not important when
studying the early phase after transplantation.
Several factors could explain the differences in immune
reconstitution among the different cell source groups. In
u-BM and id-Sib recipients, bothmature antigen-speciﬁc and
naïve donor T lymphocytes are infused, whereas in u-CB
recipients, T cells are mainly naïve and antigen-
inexperienced. In the early phase, CD8þ T cell- immune
reconstitution results predominantly from peripheral
expansion in u-BM recipients [45]. Furthermore, T cell counts
are approximately 10-fold higher in u-BM grafts than in u-CB
grafts. Given the fact that all recipients in this study were
given an identical dose of ATG before u-BM and u-CB
transplantation, the in vivo T cell depletion after u-CB HSCT
will leave fewer T cells to proliferate compared with u-BM
and id-Sib HSCT (in which no ATG is given). The low
proportion of naïve CD4þ and CD8þ cells in u-CB recipients
may also be related to the use of ATG. Pearl et al. [46]
reported that a high prevalence of T cells after ATG admin-
istration are mainly of the effector-memory phenotype.
Granulocyte colony-stimulating factor may also cause alter-
ations in T cell subsets [35,47]. Although CD4þ T cell help is
required to promote B cell maturation, T cell lymphopenia
may facilitate B cell expansion. This hypothesis was
conﬁrmed in patients with HIV infection or idiopathic T cell
lymphopenia, who exhibited an expansion of immature B
cells [48,49]. Alternatively, the higher proliferative capacity
of u-CB stem cells may be associated with the higher
numbers of B cells early after HSCT. Differences in critical
cytokines or growth factors might also be responsible for
differences in immune reconstitution among recipients of
transplantations from different cell sources [50]. These
differences among the 3 groups might explain the variable
kinetics of immune reconstitution early after HSCT.
The unique features of immune recovery mean that each
cell source has its own advantages and disadvantages [51,52].
The delayed T cell immune recovery in u-CB recipients is
associated with a higher risk of infection-related complica-
tions within the ﬁrst 90 days post-HSCT [10]. However, in
a retrospective study of 785 children with acute leukemia,AUC0e90 combined with a peak in CD4þ cell count during the ﬁrst 90 days
post-HSCT for the 3 groups combined.
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free survival in matched u-CB recipients, 1- or 2-
antigenemismatched u-CB recipients, and u-BM recipients,
but a better outcome in fully matched u-CB recipients.
Apparently, despite poor immune reconstitution, relapse
rates are not inﬂuenced by the delayed immune reconstitu-
tion in u-CB recipients. Eradication of residual leukemic cells
by NK cells may play a crucial role in the control of relapse
[54]. Our results suggest that the rapid immune reconstitu-
tion of NK cells in u-CB recipients explains the relatively good
outcomes after u-CB HSCT.
A potential limitation of this study is the heterogeneous
nature of our cohort with regard to diagnosis, age, and
conditioning regimens used (total body irradiatione or
busulfan-based). Owing to the relatively small number of
patients in each of the 3 cell source groups, we were unable
to analyze associations between immune reconstitution and
mortality by group. On the other hand, this heterogeneity
allows our ﬁndings to be extrapolated to children in other
transplantation centers. In future analyses, it may be of
interest to include more covariates, such as timing and
dosing of ATG (preferably active ATG levels), drug combina-
tions used in the conditioning regimen [55,56], and some
other immune marker (eg, innate immunity, Tregs). Another
limitation of this study is the relatively small dataset. In
a larger dataset, it would be interesting to study speciﬁc
causes of mortality (eg, relapse, transplantation-related) to
determine whether CD4þ levels are consistently predictive
for the separate causes. The strengths of this study include
the large number of measurements per patient as well as the
straightforward mathematical approach for describing the
kinetics of immune reconstitution. The CD4þ cutoff value of
4,300 cells/day between 0 and 90 days post-HSCT can be
easily implemented in clinical practice (with the trapezoidal
method [((cell numbertime yþ cell numbertime x)/2) 
(timey timex] using theWeb application available at http://
www.umcutrecht.nl/subsite/SCT-kinderen/Professionals/PKPD-
studies/AUC-CD4-calculation) to identify those patients at
greatest risk early after allogeneic HSCT. The combination of
CD4þ AUC0-90 and occurrence of a peak CD4þ cell count can
be used to improve and speed implementation of adjuvant
treatment. The recovery of T helper cell counts could serve as
a pharmacodynamic surrogate endpoint when studying the
pharmacodynamicepharmacokinetic relationships of drugs
used in HSCT in future studies. Such analyses will also make
it possible to optimize and tailor the dosing of immuno-
suppressive drugs, such as ATG (one of the most important
determinants of immune reconstitution), or novel adjuvant
immune therapies.
In conclusion, NK and CD4þ cells play a protective
role early post- HSCT. The kinetics of T cell, B cell, and
NK cell reconstitution early after HSCT differed among id-Sib,
u-BM, and u-CB recipients. The area under the CD4þ
cell-time curve, combined with the occurrence of a peak
in CD4þ cell count within the ﬁrst 90 days after HSCT,
can be used to predict mortality early after HSCT in
children independent of stem cell source. Future studies
should investigate immune reconstitution by stem cell
source. Finally, the kinetics of CD4þ cells may be used in
pharmacokineticepharmacodynamic studies aimed at indi-
vidualizing various immunosuppressive agents (eg, ATG).ACKNOWLEDGMENTS
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AUC0-90 AND DEFINITION OF PEAK
The dots show the cell numbers of CD4þ cells measured
at each time point. The AUC is calculated using the shaded
area using the trapezoidal method:
P
(Cell numbertimey þ
cell numbertimex)/2)*(timey  timex). The occurrence of
a peak in this patient is shown as the gray dotted line and
was deﬁned asmore than 1.5 times increase of the number of
cells at one occurrence, in which in a later time period, the
number of cells declined back to the basic level.
APPENDIX 2: DATA ANALYSIS USING MULTIPLICATIVE
INTENSITY MODELS
The data were tested in relation with mortality using
several regression functions (linear, logarithmic, and para-
bolic). Data analysis was restricted to the data without some
extremely high values, which occurred in 1 or 2 cases per
lymphocyte subset; however, exclusion of these extreme
values did not affect the associations detected. Data for 5
patients who died within 90 days were included by extrap-
olation and excluded from the AUC0-90 analyses. The results
of the 2 analyses were similar. (The extrapolated data arediscussed in the Results, to show associations within and
after the ﬁrst 90 days.)
The different models were compared using HRs, P values,
and the diagnostics of the model (residuals vs the covariate).
Age, sex, and the occurrence of a peak in CD4þ or CD8þ cell
count in the ﬁrst 90 days were included as covariates.
Separate regression analyses were performed for each cell
source. If the models for a speciﬁc subset were similar in the
3 groups, then the data were combined, and baseline hazard
functions (using Cox regression) were stratiﬁed for the 3
groups. If a signiﬁcant association between the kinetics of
a speciﬁc lympohocyte subset and mortality was estimated,
then the value for this cell type at day þ90 was used to see
whether there was a similar association. This cross- sectional
single-point measurement of a lymphocyte subset is
currently the most commonly used approach.APPENDIX 3: DATA ANALYSIS USING ROC CURVES
A time-dependent version of ROC curves was used. At
1 year and 2 years, patients were divided into 2 mutually
exclusive groups: cases and controls. The cases were those
patients who had died, and the controls were the patients
who were still alive at this moment in time. Corresponding
ROC curves at 1 year and 2 years were deﬁned (ie, graphical
plots of the sensitivity, or true positive rate, vs speciﬁcity, or
false-positive rate). The area under the ROC curve (AUCROC)
that summarizes the predictive power of the model as
a single number was computed by numerical integration of
the ROC curve equation by the trapezoidal method. A cutoff
value of the lymphocyte subset was determined by esti-
mating the AUCROC value for each of the observed cell counts.
The cell count with the highest AUCROC value was considered
the optimal cutoff value. Kaplan-Meier plots were created to
show the association between this cutoff value and survival.
